Increase/Decrease in Cash: The total change in cash for the company over the given period.
Inhibikase Therapeutics, Inc. (IKT) had Increase/Decrease in Cash of $-89.65M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-16.38M |
|
-- |
|
-- |
|
$17.84M |
|
$-17.84M |
|
$1.46M |
|
$-16.38M |
|
$-16.38M |
|
$-16.38M |
|
$-16.38M |
|
$-16.38M |
|
$-16.38M |
|
$-17.84M |
|
$-17.84M |
|
172.31M |
|
172.31M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$172.18M |
|
-- |
|
$1.16M |
|
$173.33M |
|
$5.71M |
|
-- |
|
-- |
|
$5.71M |
|
$167.62M |
|
$167.62M |
|
$167.62M |
|
132.03M |
|
| Cash Flow Statement Financials | |
$-12.06M |
|
$-80.48M |
|
$2.90M |
|
$139.22M |
|
$49.57M |
|
|
Increase/Decrease in Cash |
$-89.65M |
$5.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
30.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.77% |
|
-9.77% |
|
-9.45% |
|
-9.77% |
|
$1.27 |
|
$-0.07 |
|
$-0.07 |
|